Examqo › Examqo library › Urology › Urological oncology · IMLE
Upper tract urothelial carcinoma (UTUC)
A urothelial tumour of the renal pelvis or ureter is divided into low risk, treated with kidney sparing (endoscopic or segmental resection), and high risk, treated with radical nephroureterectomy with a bladder cuff (RNU).
Why it matters in the exam
UTUC accounts for 5 to 10 percent of urothelial tumours. Risk factors: smoking, aristolochic acid (Balkan nephropathy), long-term phenacetin use and Lynch syndrome — every UTUC patient under age 60 or with a family history needs evaluation for Lynch. The common symptom is haematuria, sometimes flank pain from obstruction. Evaluation: CT urography (the best test), urine cytology, ureteroscopy with biopsy, and cystoscopy — because some patients also have a bladder tumour.
Under EAU, low risk: a single tumour, smaller than 2 cm, low-grade cytology and biopsy, and no signs of invasion on CT; then kidney-sparing treatment — laser ablation at ureteroscopy or distal ureterectomy. High risk: hydronephrosis, a tumour of 2 cm or more, high-grade cytology or biopsy, multifocality, suspected invasion on CT, previous cystectomy for high-grade bladder cancer or a histological variant; then radical nephroureterectomy including a bladder cuff, and in muscle-invasive disease — template lymph node dissection.
After RNU the bladder recurrence rate is high, so a single postoperative instillation of chemotherapy (mitomycin C) into the bladder is recommended, with cystoscopic follow-up. In stage pT2 to pT4 disease or with positive nodes, adjuvant platinum-based chemotherapy is given (POUT trial), and for some patients adjuvant immunotherapy with nivolumab. With a solitary kidney or poor renal function, kidney sparing is considered even in higher-risk tumours, with close follow-up. The link between an upper tract urothelial tumour and a bladder tumour runs both ways, so follow-up always covers both systems.
Key points
- 5 to 10 percent of urothelial tumours.
- CT urography, cytology and ureteroscopy.
- Low risk — kidney sparing.
- High risk — RNU with a bladder cuff.
- After RNU — a single instillation of mitomycin C.
Summary table
| Group | Criteria | Treatment |
|---|---|---|
| Low risk | Single, smaller than 2 cm, low grade, no invasion | Endoscopic ablation or segmental resection |
| High risk | Hydronephrosis, 2 cm or more, high grade, multifocal | RNU with a bladder cuff |
| After RNU | Risk of bladder recurrence | Single instillation of mitomycin C and cystoscopy |
| pT2 to pT4 or positive nodes | Locally advanced disease | Adjuvant platinum-based chemotherapy |
| Under age 60 or family history | Suspected Lynch syndrome | Genetic evaluation |
In the full version for subscribers
- A simple algorithm
- Memory aid
- Exam traps
- 5 review cards
- Enough for IMLE
The full version is open to subscribers of: Urology, Medical licensing exam (IMLE), Oncology.
Subscriber? Read the full topic Plans and prices 25 free questions
Sources
- EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma, 2025 edition — Diagnosis, risk stratification and disease management
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (upper tract urothelial carcinoma section), 2025 — Upper tract urothelial carcinoma
- Campbell-Walsh-Wein Urology, 12th edition (2020) — Urothelial Tumors of the Upper Urinary Tract and Ureter
Sources are given for further reading; the text is written afresh and not copied from them.
Reviewed by the Examqo AI Professor · 2026-11-06. The text may contain errors; when in doubt, check the source.